Intas Pharma launches Rituximab biosimilar

With the launch of Mabtas, Intas becomes the only Indian company to have indigenously developed 6 biosimilars in the Indian market


Intas Pharmaceuticals has launched "Mabtas",a biosimilar version of Rituximab, with a view to make Non-Hodgkin's Lymphoma (NHL) treatment cost-effective . Mabtas is competent in treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells like Chronic Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis apart from NHL.

Mabtas is Asia's only EU GMP facility of Intas Biopharmaceuticalsa at Ahmedabad. With the launch of this product, Intas now is the only company to have indigenously developed 6 biosimilars in the domestic market. Intas Biopharmaceuticals is India's first and only biopharmaceutical companies to receive European Union - Good Manufacturing Practice (EU-GMP) certification for its microbial manufacturing facility and only company having product under-registration with EMA.

Intas Biopharmaceuticals is already a leading manufacturer of Erythropoietin, G-CSF and peg G-CSF for India and have introduced world's first biosimilar peg G-CSF. Mabtas marks the first monoclonal antibody (mAb) launch from Intas. With this product Intas joins the ranks of select few Indian companies to launch a mAb product in the domestic market.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email